Valuation : Regeneron Pharmaceuticals, Inc.

Market Cap 8.51TCr 7.34TCr 6.92TCr 6.3TCr 12TCr 8,03900Cr 12TCr 82TCr 32TCr 4,11000Cr 32TCr 31TCr 13,50100Cr P/E 2026 *
19.7x
P/E 2027 * 16.9x
Enterprise Value 7.82TCr 6.75TCr 6.36TCr 5.79TCr 11TCr 7,39000Cr 11TCr 75TCr 29TCr 3,77800Cr 29TCr 29TCr 12,41200Cr EV / Sales 2026 *
4.62x
EV / Sales 2027 * 4.05x
Free-Float
71.06%
Yield 2026 *
0.46%
Yield 2027 * 0.52%
1 day+3.42%
1 week+4.57%
Current month+6.63%
1 month+11.72%
3 months+41.32%
6 months+7.74%
Current year+10.39%
1 week 779.08
Extreme 779.08
854.49
1 month 747
Extreme 747
854.49
Current year 591.52
Extreme 591.52
854.49
1 year 541
Extreme 541
854.49
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap. Importance
19/08/26 Exercice

General Counsel

33,583 0.0326%
18/08/26 Exercice

Chief Financial Officer

17,165 0.0167%
10/08/26 Exercice

Director

1,200 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+3.42%+4.57%+47.44%+2.45% 8.23TCr
-2.24%+0.77%+523.44%+33.98% 6.16TCr
+0.45%+1.17%-16.27%-35.01% 5.9TCr
-1.25%-5.30%-1.98%+33.18% 5.12TCr
+0.92%-0.23%+11.50%+165.47% 4.83TCr
+3.07%+0.72%+59.47%-16.66% 3.19TCr
+3.06%+0.55%+49.84%+99.15% 2.53TCr
+0.20%-7.29%-3.32%+190.03% 2.26TCr
-0.52%-1.98%+65.45%+115.64% 1.66TCr
-0.83%-2.29%-14.71%+786.97% 1.53TCr
Average +0.62%-1.90%+72.08%+137.52% 4.14TCr
Weighted average by Cap. +0.73%-1.86%+95.58%+72.75%

Financials

2026 *2027 *
Net sales 1.69TCr 1.46TCr 1.38TCr 1.25TCr 2.34TCr 1,59800Cr 2.36TCr 16TCr 6.32TCr 82TCr 6.35TCr 6.22TCr 2,68500Cr 1.84TCr 1.59TCr 1.5TCr 1.36TCr 2.55TCr 1,74000Cr 2.57TCr 18TCr 6.88TCr 89TCr 6.92TCr 6.76TCr 2,92200Cr
Net income 477.34Cr 411.8Cr 387.92Cr 353.44Cr 660.64Cr 45TCr 665.6Cr 4.59TCr 1.78TCr 23TCr 1.79TCr 1.75TCr 76TCr 544.54Cr 469.77Cr 442.54Cr 403.2Cr 753.65Cr 51TCr 759.3Cr 5.24TCr 2.03TCr 26TCr 2.04TCr 2TCr 86TCr
Net Debt -686.84Cr -592.53Cr -558.18Cr -508.57Cr -950.6Cr -65TCr -957.73Cr -6.61TCr -2.56TCr -33TCr -2.58TCr -2.52TCr -1,09000Cr -1.06TCr -910.48Cr -857.69Cr -781.46Cr -1.46TCr -1LCr -1.47TCr -10TCr -3.94TCr -51TCr -3.96TCr -3.88TCr -1,67400Cr
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
02/26/02 $852.23 +3.45% 7,49,199
01/26/01 $823.82 +3.10% 6,82,806
31/26/31 $799.08 +0.62% 8,94,268
28/26/28 $794.19 -1.67% 4,88,305
27/26/27 $807.71 -0.87% 7,66,990
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
852.23USD
Average target price
840.43USD
Spread / Average Target
-1.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock